Yannick Jurriaan Maria Aarts

Yannick Jurriaan Maria Aarts

Auto-generated profile, based on publicly available information

Yannick Jurriaan Maria Aarts

Wageningen University & Research, Adaptation Physiology Group, Wageningen, the Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EREve Richardson
Eve Richardson
YAYannick Jurriaan Maria Aarts
Yannick Jurriaan Maria Aarts
JAJohn A Altin
John A Altin
CBCoos A. B. Baakman
Coos A. B. Baakman
PBPhilip Bradley
Philip Bradley
BPBjoern Peters
Bjoern Peters
T cell receptors (TCRs) can bind to peptides presented by MHC molecules (pMHC) as a first step to trigger a T cell response. Reliable approaches to predict TCR:pMHC binding would have broad applications in clinical diagnostics, therapeutics, and the fundamental understanding of molecular interactions. IMMREP is a community organized series of prediction contests that asks participants to predict TCR:pMHC binding on unpublished datasets. Previous iterations in 2022 and 2023 showed multiple approaches can predict TCR-pMHC binding with significant accuracy (median AUC_0.1≥0.7) for peptides where experimental data is available (“seen” peptides). In contrast, models did not outperform random guessing for peptides that have no such data available (“unseen” peptides). Here we report on the results of IMMREP25, which focused solely on unseen peptides in order to evaluate the cutting edge of the field. We received 126 named submissions predicting the specificity of 1,000 TCRs against twenty unseen peptides restricted by one of two MHC molecules (HLA-A*02:01 and HLA-B*40:01). The best performing methods showed a macro-AUC_0.1 of 0.60, significantly better than random, demonstrating significant advances in the field. The top performing methods incorporated structural modeling into their approach, indicating that especially for ‘unseen’ peptides, a structural understanding aids in the prediction of TCR:pMHC interactions. The results from this benchmark highlight the significant challenges remaining for TCR:pMHC predictions and will inform future method development.

22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CBCoos Baakman
Coos Baakman
GCGiulia Crocioni
Giulia Crocioni
CGCunliang Geng
Cunliang Geng
DRDaniel Tobias Rademaker
Daniel Tobias Rademaker
DFDavid Frühbuß
David Frühbuß
LXLi C. Xue
Li C. Xue
Identifying tumor peptides that bind patient MHC proteins and elicit immune responses is central to immunotherapy, yet progress remains limited to a handful of well-studied alleles. Structure-based methods generalize better than sequence-only models but are constrained by the high computational cost of 3D modeling. We present SwiftMHC, the fastest structure-based framework for peptide–MHC (pMHC) modeling and binding affinity prediction. SwiftMHC predicts peptide–MHC binding in 0.009 sec/case in batch mode on a single A100 GPU—nearly an order of magnitude faster than leading sequence-based methods such as NetMHCpan 4.1 (0.081 sec/case)—while performing competitively in predictive accuracy. In addition to affinity estimation, SwiftMHC generates all-atom 3D pMHC structures and achieves a median Cα-RMSD of 1.32 Å against X-ray benchmarks, matching or better than the accuracy of state-of-the-art approaches (e.g., AlphaFold with fine-tuning) but running thousands of times faster (excluding disk-writing time). These results demonstrate the power of task-specific AI trained on physics-derived synthetic data to overcome the scarcity of experimental structures. Optimized for HLA-A*02:01 9-mers but readily extensible to other alleles, SwiftMHC enables rapid and accurate identification of peptides distinct from self at T-cell–exposed surfaces. This capability may expand immunotherapy targets, improve the safety of TCR-based therapies, and accelerate the development of next-generation cancer immunotherapies.

1 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FPFarzaneh M. Parizi
Farzaneh M. Parizi
YAYannick J. M. Aarts
Yannick J. M. Aarts
NSNils Smit
Nils Smit
DADona Roran Ar
Dona Roran Ar
DDDaniëlle Diepenbroek
Daniëlle Diepenbroek
LXLi C. Xue
Li C. Xue
The T cell’s ability to discern self and non-self depends on its T cell receptor (TCR), which recognizes peptides presented by MHC molecules. Understanding this TCR-peptide-MHC (TCRpMHC) interaction is important for cancer immunotherapy design, tissue transplantation, pathogen identification, and autoimmune disease treatments. Understanding the intricacies of TCR recognition, encapsulated in TCRpMHC structures, remains challenging due to the immense diversity of TCRs (>10 8 /individual), rendering experimental determination and general-purpose computational docking impractical. Addressing this gap, we have developed a rapid integrative modeling protocol leveraging unique docking patterns in TCRpMHC complexes. Built upon PIPER, our pipeline significantly cuts down FFT rotation sets, exploiting the consistent polarized docking angle of TCRs at pMHC. Additionally, our ultra-fast structure superimposition tool, GradPose, accelerates clustering. It models a case in 3-4 minutes on 12 CPUs, showcasing a speedup of up to 25-40 times compared to the ClusPro webserver. On a benchmark set of 38 TCRpMHC class I (TCRpMHC-I) complexes, our protocol outperforms the state-of-the-art docking tools in model quality. This protocol can potentially provide structural information to TCR repertoires targeting specific peptides. Its computational efficiency can also enrich existing pMHC-specific single-cell sequencing TCR data, facilitating the development of structure-based deep learning (DL) algorithms. These insights are essential for understanding T cell recognition and specificity, advancing the development of therapeutic interventions.